Development of Nipah virus mRNA vaccine

在本研究中，我们开发并优化了一种稳健的高通量（384孔格式）ELISA结合测定法，以量化尼帕病毒（NiV）融合前（pre-F）和糖蛋白（G）特异性血清抗体结合反应。我们还开发并优化了一种高度可重复的基于NiV慢病毒载体的假型中和试验，用于96孔和384孔格式。来自用尼帕病毒前F或G蛋白免疫的恒河猴的血清样品用于优化和验证这些测定。然后使用这些NiV ELISA结合和中和试验评估NiV mRNA-1215疫苗诱导的血清抗体应答，以确定与前F和单体G蛋白的结合，以及在接种疫苗的非洲绿色猴（AGM）（研究VRC-22-0989）和人（研究VRC 322）中NiV假型病毒的中和。

For this study we developed and optimized a robust, high-throughput (384-well format) ELISA binding assay to quantify Nipah virus (NiV) pre-fusion (pre-F)- and glycoprotein (G)-specific serum antibody binding responses. We also developed and optimized a highly reproducible NiV lentivirus vector-based pseudo-typed neutralization assay for both 96-well and 384-well formats. Serum samples from rhesus macaques immunized with Nipah virus pre-F or G proteins were used to optimize and validate these assays. These NiV ELISA binding and neutralization assays were then used to assess NiV mRNA-1215 vaccine-induced serum antibody responses for binding to pre-F and monomeric G proteins, and for neutralization of NiV pseudo-typed virus in vaccinated African green monkeys (AGM) (study VRC-22-0989) and humans (study VRC322).